Hormone therapy: A 3-part CME series

Long-term use of hormone therapy, quality of life, and statins
(Part 3 of 3)

Program Chair, Principal Scientist and Medical Director, Jackson Hole Center for Preventive Medicine, Jackson Hole, Wyoming; Adjunct Scholar in Epidemiology, University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, Pennsylvania; Professor of Family and Preventive Medicine, University of California, San Diego (retired)

Professor of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, New York

Clinical Professor of Obstetrics and Gynecology, George Washington University, President and Medical Director, James A. Simon, MD, PC, Women’s Health & Research Consultants^®, Washington, DC

Continue to newsletter
Click here to take the free CME/CE test online

1.0 CME credit available
Release Date: October 1, 2009
Expiration Date: October 1, 2010

For more information on this topic, read the first newsletter and the second newsletter.

Learning objectives

After reviewing this material, clinicians should be better able to:

• Describe the practical implications of recent reports in the medical literature concerning the safety of hormone therapy

• Discuss issues that should be considered in terms of agent selection

• Review strategies to prescribe the most appropriate agent for the individual patient

• Assess the relevant medical literature that supports the course of treatment

Target audience

This activity has been designed for obstetricians/gynecologists, and other health care professionals who are interested in learning more about the use of progesterone in the menopausal transition.

CME accreditation statement

The University of Cincinnati designates this educational activity for a maximum of 1.0 AMA PRA Category 1 credit^™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the University of Cincinnati College of Medicine. The University of Cincinnati College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Financial disclosures and conflicts of interest

According to the disclosure policy of the University of Cincinnati, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity. All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Robert D. Langer, MD, MPH, is a consultant for Wyeth Pharmaceuticals as an expert witness.

Rogerio A. Lobo, MD, reports that he has no relevant financial relationship(s) with any commercial interests.

James A. Simon, MD, CCD, NCMP, FACOG, has served as a consultant or on the advisory boards of Allergan Inc.; The Alliance for Better Bone Health; Amgen Inc.; Ascend Therapeutics, Inc.; Barr Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals; BioSante Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Concert Pharmaceuticals, Inc.; Corcept Therapeutics Incorporated; Depomed, Inc.; GlaxoSmithKline; KV Pharmaceutical Company; Meditrina Pharmaceuticals, Inc.; Merck & Co., Inc.; Merrion Pharmaceuticals, Inc.; Nanma/Tripharma/Trinity; Novo Nordisk A/S; Novogyne Pharmaceuticals; Pear Tree Pharmaceuticals; QuatRx Pharmaceuticals Company; Roche; Schering-Plough Corporation; Sciele Pharma, Inc.; Solvay Pharmaceuticals, Inc.; Ther-Rx Corporation; Warner Chilcott; and Wyeth Pharmaceuticals. He has received grant/research support from BioSante Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals; FemmePharma Global Healthcare, Inc.; GlaxoSmithKline; Nanma/Tripharma/Trinity; Novartis Pharmaceuticals Corp.; and Procter & Gamble. He has also served on the speakers’ bureaus of Amgen Inc.; Ascend Therapeutics, Inc.; Barr Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; KV Pharmaceutical Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corp.; Novogyne Pharmaceuticals; Sciele Pharma, Inc.; Ther-Rx Corporation; Warner Chilcott; and Wyeth Pharmaceuticals.

Planning Committee: Kay Weigand, University of Cincinnati, has disclosed no relevant financial relationship(s) with any commercial interests; Robert D. Langer, MD, MPH, is a consultant for Wyeth Pharmaceuticals as an expert witness; Carolyn Tillona for Quadrant HealthCom Inc. has disclosed no relevant financial relationship(s) with any commercial interests.

Off-label and unapproved agents discussed: None

Acknowledgement

This CME activity was developed through the joint sponsorship of the University of Cincinnati and Quadrant HealthCom Inc.. It was edited and peer reviewed by OBG Management.

Statement of support

This CME activity is supported by an educational grant from Solvay Pharmaceuticals, Inc.

OBG Management ©2009 Quadrant HealthCom Inc.